FPR2 and neoplasm: After orthotopic injection of T387 tumor cells into either NSG-Ccr2RFP/wt-Cx3cr1GFP/wt or NSG-Ccr2RFP/RFP-Cx3cr1GFP/wt mice and confirmation of tumor engraftment via bioluminescence imaging we started treatment with anti-CD47 (250 μg Hu5F9-G4 three times a week) or human IgG control.